UnitedHealthcare Community Plan

BYETTA / VICTOZA

PRIOR AUTHORIZATION REQUEST FORM

Complete ENTIRE form and Fax to: 866-940-7328

Today's Date

SECTION A - PATIENT INFORMATION

First Name:	Last Name:	Member ID:
Address:		
City:	State:	Zip:
Phone:	DOB:	Allergies:
Primary Insurance:	Policy #:	Group #:

Is the requested medication NEW ☐ or a CONTINUATION of THERAPY☐? If so, start date:____________

Is this patient currently hospitalized? ☐ Yes ☐ No

SECTION B - PHYSICIAN INFORMATION

First Name:		Last Name: M.D./D.O.		
Address:		City:	State:	Zip:
Phone:	Fax:	NPI #:	Specialty:	
Office Contact Name / Fax Attention to:				

SECTION C - MEDICAL INFORMATION

Medication: **Strength:**

Directions for use:

Diagnosis (Please be specific & provide as much information as possible): **ICD-10 CODE:**

Which of the following diagnoses does this member have:

☐ **Diabetes Type I** ☐ **Diabetes Type II** ☐ **Other (Please Specify)** ____________________

Will the member take any of the following medications along with Byetta or Victoza? (Check all that apply)

☐ **Glyset** ☐ **Aracarbose** ☐ **Starlix**

☐ **Prandin** ☐ **Insulin (specify type)** ________________________

Other Medications tried PREVIOUSLY *(please provide complete documentation)*

Medications	Strength	Directions	Dates of Therapy	Reason for failure / discontinuation

Additional Clinical information to support this request: ____

____

*****FOR REAUTHORIZATION REQUESTS ONLY*****

Has the patient's glycemic control improved as evidenced by a decrease in the HbA1c level? Yes or No (circle answer) If yes, please provide current HbA1c and date drawn:

HbA1c______________________ **Date Drawn:** ______________________

Physician Signature: ____ **Date:** ____________________

Confidentiality Notice: This transmission contains confidential information belonging to the sender and UnitedHealthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.